drugset / Trial / NCT03572491

Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine

NCT03572491

NaSingle-groupOpen-labelPrevention

Summary

The study is Multicenter, phase 3, Open-Label trial that explored the preventive effectiveness, safety and immunogenicity of single dose a allantoic split inactivated seasonal influenza vaccine in healthy adults.

Timeline

Start
2017-09-18
Primary completion
2018-05-21
Completion
2018-05-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Influenza Virus Vaccine Vaccine Intramuscular

Indications